OS Therapies Announces the Publication of Four Articles on OST-HER2 and Osteosarcoma in Drug Discovery World
OS Therapies will present 2.5-year overall survival data from its Phase 2b clinical trial of OST-HER2 at the ASCO Annual Meeting in late May 2026. The company reiterated its plan to submit a Biologics License Application (BLA) for OST-HER2 in osteosarcoma in the second half of 2026, leveraging its Orphan Drug, Fast Track, and Rare Pediatric Disease designations.
Key figures
- Drug Name
- OST-HER2
- Phase Of Trial
- Phase 2b
- Ascos meeting dates
- May 28, 2026 to June 2, 2026
- Bla submission target
- H2 2026
- Surival data timeframe
- 2.5 year overall survival
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.